Evidence map›Paper›PMID 42488209›Full record

SynthesisFrontiers in nutrition2026

Bibliometric and visual analysis of omega-3 polyunsaturated fatty acids in cancer research (2000-2025).

Cuicui Gao, Yanyan Li, Hui Su, Xiao Yu, Xiangqian Lu, Xin Liang, Feifei Tao, Xiaomeng Duan

Abstract readSystematic Review
In one paragraph

Synthesis in Frontiers in nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Cuicui GaoDepartment of Clinical Nutrition, Liaocheng People's Hospital, Liaocheng, China.
Yanyan LiDepartment of Clinical Nutrition, Liaocheng People's Hospital, Liaocheng, China.
Hui SuDepartment of Oncology, Liaocheng People's Hospital, Liaocheng, China.
Xiao YuDepartment of Radiation Oncology, Liaocheng People's Hospital, Liaocheng, China.
Xiangqian LuDepartment of Radiation Oncology, Liaocheng People's Hospital, Liaocheng, China.
Xin LiangDepartment of Clinical Nutrition, Liaocheng People's Hospital, Liaocheng, China.
Feifei TaoDepartment of Clinical Nutrition, Liaocheng People's Hospital, Liaocheng, China.
Xiaomeng DuanDepartment of Clinical Nutrition, Liaocheng People's Hospital, Liaocheng, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: Omega-3 polyunsaturated fatty acids (PUFAs) have received considerable attention as potential adjunctive agents in antitumor therapy. However, systematic bibliometric analyses of this research area remain limited. This study aims to systematically examine research trends, knowledge hotspots, and emerging themes related to omega-3 PUFAs in oncology from 2000 to 2025, with the goal of providing valuable insights for future investigations. Methods: Records related to omega-3 PUFAs and oncology published between 2000 and 2025 were retrieved from the Web of Science Core Collection and Scopus. Bibliometric mapping was performed using R/bibliometrix, VOSviewer, and CiteSpace. In addition, clinical trial records from PubMed were screened to summarize clinical progress in this field. Results: A total of 2,917 publications from the Web of Science and 7,380 publications from Scopus were analyzed. From 2000 to 2025, the annual number of publications in this field increased gradually, then reached a plateau, followed by a slight decline. The United States was the leading contributor in terms of publication output ( Conclusion: Research on omega-3 PUFAs in oncology is progressively shifting from mechanistic exploration toward clinically oriented and translational applications. Emerging trends emphasize the integration of molecular mechanisms, objective exposure biomarkers, and clinical intervention strategies within a precision-oriented nutritional oncology framework. Future studies should focus on standardized exposure assessment, dose-response modeling, patient stratification, and clinically meaningful endpoints to better define target populations, optimal formulations and dosages, and appropriate intervention windows.

Indexed as

applicationsbibliometricscancerepidemiologyinflammationomega-3 PUFAstherapeutic

Identifiers

PMID42488209
PMCPMC13388407

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.